Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hai… Read more
Genomma Lab Internacional S.A.B. de C.V (GNMLF) - Total Liabilities
Latest total liabilities as of June 2025: $13.01 Billion USD
Based on the latest financial reports, Genomma Lab Internacional S.A.B. de C.V (GNMLF) has total liabilities worth $13.01 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genomma Lab Internacional S.A.B. de C.V - Total Liabilities Trend (2013–2024)
This chart illustrates how Genomma Lab Internacional S.A.B. de C.V's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genomma Lab Internacional S.A.B. de C.V Competitors by Total Liabilities
The table below lists competitors of Genomma Lab Internacional S.A.B. de C.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Astra Microwave Products Limited
NSE:ASTRAMICRO
|
India | ₹6.04 Billion |
|
HBL ENGINEERING LTD
NSE:HBLENGINE
|
India | ₹6.92 Billion |
|
Business First Bancshares Inc
NASDAQ:BFST
|
USA | $7.32 Billion |
|
CJ CheilJedang Corp
KO:097955
|
Korea | ₩18.42 Trillion |
|
Taysha Gene Therapies Inc
NASDAQ:TSHA
|
USA | $97.56 Million |
|
Fujian Qingshan Paper Industry Co Ltd
SHG:600103
|
China | CN¥1.66 Billion |
|
PVR INOX Ltd.
NSE:PVRINOX
|
India | ₹89.87 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Genomma Lab Internacional S.A.B. de C.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genomma Lab Internacional S.A.B. de C.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genomma Lab Internacional S.A.B. de C.V (2013–2024)
The table below shows the annual total liabilities of Genomma Lab Internacional S.A.B. de C.V from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $581.91 Million | -12.38% |
| 2023-12-31 | $664.14 Million | +13.09% |
| 2022-12-31 | $587.25 Million | +5.14% |
| 2021-12-31 | $558.53 Million | -10.96% |
| 2020-12-31 | $627.26 Million | +5.00% |
| 2019-12-31 | $597.37 Million | +10.47% |
| 2018-12-31 | $540.75 Million | +19.72% |
| 2017-12-31 | $451.66 Million | +4.37% |
| 2016-12-31 | $432.77 Million | -10.85% |
| 2015-12-31 | $485.46 Million | -96.75% |
| 2014-12-31 | $14.93 Billion | +75.23% |
| 2013-12-31 | $8.52 Billion | -- |